Beta-blocker usage after malignant melanoma diagnosis and survival: A population-based nested case-control study

British Journal of Dermatology

Volumn 170, Issue 4, 2014, Pages 930-938

  McCourt, C ^a,b   Coleman, H G ^b   Murray, L J ^b   Cantwell, M M ^b   Dolan, O ^a,b   Powe, D G ^c   Cardwell, C R ^b  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ANTINEOPLASTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; LABETALOL; METOPROLOL; NEBIVOLOL; OXPRENOLOL; PINDOLOL; PROPRANOLOL; SOTALOL; TIMOLOL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG FATALITY; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIMODALITY CANCER THERAPY; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; CASE CONTROL STUDY; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; ONSET AGE; SKIN NEOPLASMS; UNITED KINGDOM; VERY ELDERLY;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GREAT BRITAIN; HUMANS; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS;

EID: 84924401407     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12894     Document Type: Article

References (36)

1. Cancer Research U.K. Skin cancer incidence statistics. Available at: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/skin/incidence/ (last accessed 26 February 2014).
2. Marsden JR, Newton-Bishop JA, Burrows L, et al,. Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol 2010; 163: 238-56.
3. Aronow WS,. Current role of beta-blockers in the treatment of hypertension. Expert Opin Pharmacother 2010; 11: 2599-607.
4. Annabi B, Lachambre MP, Plouffe K, et al,. Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res 2009; 60: 438-45.
5. Chim H, Armijo BS, Miller E, et al,. Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A. Ann Surg 2012; 256: 146-56.
6. Greenberger S, Bischoff J,. Infantile hemangioma-mechanism(s) of drug action on a vascular tumor. Cold Spring Harb Perspect Med 2011; 1: a006460.
7. Storch CH, Hoeger PH,. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 2010; 163: 269-74.
8. Entschladen F, Drell TL 4th, Lang K, et al,. Neurotransmitters and chemokines regulate tumor cell migration: potential for a new pharmacological approach to inhibit invasion and metastasis development. Curr Pharm Des 2005; 11: 403-11.
9. Ganz PA, Cole SW,. Expanding our therapeutic options: beta blockers for breast cancer? J Clin Oncol 2011; 29: 2612-16.
10. Powe DG, Voss MJ, Zänker KS, et al,. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010; 1: 628-38.
11. Sanzo M, Colucci R, Arunachalam M, et al,. Stress as a possible mechanism in melanoma progression. Dermatol Res Pract 2010; 2010: 483493.
12. Scarparo AC, Sumida DH, Patrão MT, et al,. Catecholamine effects on human melanoma cells evoked by alpha1-adrenoceptors. Arch Dermatol Res 2004; 296: 112-19.
13. Simonetti O, Lucarini G, Brancorsini D, et al,. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Cancer 2002; 95: 1963-70.
14. Yang EV, Kim SJ, Donovan EL, et al,. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun 2009; 23: 267-75.
15. Benish M, Bartal I, Goldfarb Y, et al,. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol 2008; 15: 2042-52.
16. Glasner A, Avraham R, Rosenne E, et al,. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol 2010; 184: 2449-57.
17. Lang K, Drell TL 4th, Lindecke A, et al,. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 2004; 112: 231-8.
18. Pasquier E, Ciccolini J, Carre M, et al,. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget 2011; 2: 797-809.
19. Sloan EK, Priceman SJ, Cox BF, et al,. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 2010; 70: 7042-52.
20. Palm D, Lang K, Niggemann B, et al,. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 2006; 118: 2744-9.
21. De Giorgi V, Grazzini M, Gandini S, et al,. Treatment with beta-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med 2011; 171: 779-81.
22. Lemeshow S, Sørensen HT, Phillips G, et al,. β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 2011; 20: 2273-9.
23. Jick H, Jick SS, Derby LE,. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991; 302: 766-8.
24. Balch CM, Gershenwald JE, Soong SJ, et al,. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-206.
25. Fleming ID, ed. AJCC Cancer Staging Manual. Philadelphia, PA: Lippincott-Raven, 1997.
26. Khan NF, Perera R, Harper S, Rose PW,. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 2010; 11: 1.
27. Joint Formulary Committee. Non-steroidal anti-inflammatory drugs. In: British National Formulary: BNF 60 (, Martin J, ed). London: Pharmaceutical Press, 2010; 621-629; chapter 10.1.1.
28. Azoulay L, Yin H, Filion KB, et al,. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 2012; 344: e3645.
29. Schade R, Andersohn F, Suissa S, et al,. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356: 29-38.
30. Levesque LE, Hanley JA, Kezouh A, Suissa S,. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010; 340: b5087.
31. Etminan M, Samii A,. Pharmacoepidemiology I: a review of pharmacoepidemiologic study designs. Pharmacotherapy 2004; 24: 964-9.
32. Essebag V, Platt RW, Abrahamowicz M, Pilote L,. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005; 5: 5.
33. Fine JP, Gray RJ,. A proportional hazards model for the sub-distribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
34. Livingstone E, Hollestein LM, van Herk-Sukel MP, et al,. β-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study. Eur J Cancer 2013; 49: 3863-71.
35. Sosman JA, Kim KB, Schuchter L, et al,. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-14.
36. Sarfati D, Blakely T, Pearce N,. Measuring cancer survival in populations: relative survival versus cancer-specific survival. Int J Epidemiol 2010; 39: 598-610.